Longevity & Aging · Supplements
quercetin decreases senescent cell burden
In plain terms: Does quercetin clear out senescent 'zombie' cells?
Contested Longevity & Aging 🐭 Non-human evidence🔬 Includes disconfirming
Part of: 🧪 quercetin
RefutedContestedStrong support
consensus score 0.14
Nearly all the research gave quercetin together with a chemotherapy drug, dasatinib, so it can't tell you what quercetin did alone. Tested on its own, results are split, including a clean negative in human cells. No completed trial has measured this properly in people.
📅 Last reviewed: 2026-07-26 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Animal studies (Animal)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
9 support 2 contradict 0 tested null 29 mixed · 40 sources, 11 independent groups
What the evidence shows
The attribution problem is the whole story. The great majority of studies measuring senescent-cell burden dose DASATINIB + QUERCETIN together, and a D+Q result cannot be assigned to quercetin — those are recorded here as mixed for exactly that reason.
The evidence (40)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Ahn H, Chung EJ, White A, Zhang H, Kwon S, K C S, Citrin DE 2026 · Radiation research | animal | supports | moderate | QUERCETIN ALONE (oral chow, no dasatinib) reduced p21+/p16+ senescent-cell counts and macrophage markers in irradiated (35Gy) mouse skin at 150 days post-irradiation vs control chow; its methylated metabolite (3-O-methylquercetin) reproduce |
| Xia X, Yi F, Zhang R, Wu R, Zhang X, Zhang Y, Liu J, Qin H, He B, Duan Y, Xu Y, Huang XF, Yu Y, Hu M 2026 · Experimental neurology | animal | mixed | moderate | D+Q in high-fat-diet (and palmitate-diet) mice significantly reduced hippocampal senescent cell burden (SA-beta-gal+ cells), suppressed p16, and normalized SASP factors, restoring cognitive function and synaptic protein expression. Combinat |
| Hickson LJ, Langhi Prata LGP, Bobart SA, Evans TK, Giorgadze N, Hashmi SK, Herrmann SM, Jensen MD, Jia Q, Jordan KL, Kellogg TA, Khosla S, Koerber DM, Lagnado AB, Lawson DK, LeBrasseur NK, Lerman LO, McDonald KM, McKenzie TJ, Passos JF, Pignolo RJ, Pirtskhalava T, Saadiq IM, Schaefer KK, Textor SC, Victorelli SG, Volkman TL, Xue A, Wentworth MA, Wissler Gerdes EO, Zhu Y, Tchkonia T, Kirkland JL 2019 · EBioMedicine | observational | mixed | moderate | D+Q COMBINATION (Mayo Clinic / Kirkland-Tchkonia group): open-label phase 1 pilot in 9 diabetic-kidney-disease patients (68.7+-3.1y) given dasatinib 100mg + quercetin 1000mg for 3 days showed reduced adipose p16INK4A+/p21CIP1+ and SA-beta-g |
| Su H, Ma R, Su D, Tan C, Zhu Y, Yang X 2026 · European journal of histochemistry : EJH | animal | mixed | moderate | DQ (dasatinib+quercetin) cleared senescent ovarian cells and reduced SASP in cyclophosphamide-induced premature-ovarian-insufficiency mice, restoring estrous cyclicity in 60% of CY+DQ mice vs ~15% of CY-alone mice (p<0.0001) and increasing |
| Tripathi U, Suda M, Kulshreshtha V, Piatkowski BT, Palmer AK, Giorgadze N, Inman C, Gasek N, Xu M, Johnson KO, Pirtskhalava T, Chaib S, Langhi Prata LPG, Zhu Y, Kandhaya-Pillai R, Tullius SG, Wyles SP, Majji R, Yalamanchili HK, Allison DB, Tchkonia T, Kirkland JL 2026 · Aging cell | in-vitro | supports | moderate | Human senescent HUVECs treated with QUERCETIN ALONE (and, in a separate arm, senescent preadipocytes treated with dasatinib alone) had 30-70% of cells killed (senolytic-sensitive), while the resistant remainder retained lower pro-inflammato |
| Orr M et al 2023 · preprint | observational | mixed | low | D+Q COMBINATION (companion report of the same 5-patient AD pilot cohort as the Nature Medicine trial above): CSF IL-6/GFAP significantly increased (t(4)=3.913 p=0.008; t(4)=3.354 p=0.028) with only a non-significant trend toward higher Abet |
| Iswarya BR, John CM 2025 · Molecular biology reports | in-vitro | supports | low | QUERCETIN ALONE (QCT, tested separately from hesperidin/HDN, not combined): in 5-fluorouracil-induced senescent A549 lung adenocarcinoma cells, quercetin significantly reversed SASP-mediated chemoresistance and inhibited migration, with X-G |
| Battaglia-Vieni A, Marchant V, Tejedor-Santamaria L, García-Caballero C, Flores-Salguero E, Ruiz-Torres MP, Rayego-Mateos S, Sanz AB, Ortiz A, Ruiz-Ortega M 2025 · Pharmaceuticals (Basel, Switzerland) | animal | contradicts | low | D+Q COMBINATION: in a murine folic-acid-induced acute kidney injury model, D+Q pretreatment did NOT reduce the number of senescent p21-positive cells in injured kidneys versus untreated (similar counts), and instead increased Cdkn1a/p21, Lc |
| Rashmi R, Gamit M, Singh G, Balachandar R, Kharkwal G 2026 · International immunopharmacology | animal | mixed | low | Systematic review/meta-analysis of 24 preclinical studies (570 animals): quercetin, alone or in combination, reduced fibrotic scores and inflammatory/oxidative markers in lung-fibrosis models, but the authors state its senolytic potential ' |
| Needy T, Heinrichs D, Maldonado V, Porter RM, Jensen H, Lowry Barnes C, Samsonraj RM 2025 · Cellular and molecular bioengineering | in-vitro | contradicts | low | QUERCETIN ALONE: 10uM quercetin applied to serially-subcultured (senescent) human mesenchymal stem cells in vitro did NOT show a consistent senolytic effect by SA-beta-gal and live/dead staining, hindered short-term proliferation in some do |
| Tripathi U et al 2025 · bioRxiv | in-vitro | supports | low | QUERCETIN ALONE (tested in human umbilical vein endothelial cells, separately from dasatinib which was tested in preadipocytes): quercetin eliminated the senolytic-sensitive fraction of senescent HUVECs (consistent with senolytics' typical |
| Kecskés S et al 2026 · bioRxiv | animal | mixed | moderate | Preprint: in aged rats with carotid stenosis plus induced ischemic stroke, chronic dasatinib+quercetin treatment reduced immunocytochemistry-assessed cerebrovascular senescent-cell burden, enhanced angiogenesis, and attenuated infarct size/ |
| Tao Z, Guo C, Xu S, Xiao X, Yang B, Wang S, Skalny AV, Tinkov AA, Aschner M, Lu R 2026 · Neurotoxicology | animal | supports | low | QUERCETIN ALONE (no dasatinib) reduced SA-beta-gal+ cells and rescued lifespan/locomotion in manganese-exposed C. elegans, and reduced beta-gal positivity, p53/p21 activation and oxidative/mitochondrial dysfunction in Mn-exposed PC12 (rat) |
| Novais EJ, Ottone OK, Jagannath S, Akande EJ, Barve RA, Risbud MV 2026 · Bone research | animal | mixed | moderate | Dasatinib+quercetin (DQ) reduced disc-degeneration grade and lowered p19ARF/p21/SASP markers in SM/J mice, while a comparator drug (Navitoclax) did not; in vitro JUN-pathway inhibition in human degenerated NP cells mimicked DQ's senescence/ |
| Battistelli LS, Moraes RM, Santos YC, Ribeiro JL, Garcia MT, Prado RF, Elefteriou F, Anbinder AL 2026 · Journal of periodontology | animal | mixed | low | Dasatinib+quercetin (D&Q, 5+50 mg/kg monthly gavage x10mo, n=24) reduced alveolar bone loss and downregulated Il6/Mmp13 in AGED mice, but failed to prevent bone loss in a separate ligature-induced periodontitis rat model (n=24) -- efficacy |
| Yan L, Zheng J, Lu Z, Zhu A, Ye M, Meng J, Tang J, Zhang H 2026 · Circulation | animal | mixed | moderate | D+Q COMBINATION: using p16-CreER;R26-tdT reporter mice after myocardial infarction, dasatinib+quercetin treatment 'selectively eliminated P16+ macrophages and fibroblasts' (directly tracked via the genetic lineage reporter), improving cardi |
| Shee S, Martinez-Martinez YB, Koleske B, Shaku MT, Yabaji S, Kobzik L, Kramnik I, Bishai W 2026 · Nature communications | animal | mixed | moderate | A THREE-drug cocktail (dasatinib+quercetin+FISETIN, not D+Q alone) given as TB adjunct therapy prolonged survival and reduced Mtb lung counts/pathology/senescence markers (p21, p16, gammaH2AX, SASP) in B6.Sst1S and aged mice, with greater b |
| Bun M, Ukon Y, Ikuta M, Kitahara T, Furuichi T, Hirai H, Tateiwa D, Kanie Y, Furuya M, Fujimori T, Otsuru S, Okada S, Kaito T 2026 · Aging cell | animal | mixed | moderate | In aged mice given high-frequency PTH 1-34 (which induced senescent osteoblast-lineage cell accumulation via mTORC1), co-administered dasatinib+quercetin reduced senescent cell burden, improved cortical porosity, and mitigated rapid post-PT |
| Wang H, Gao YC, Ming-Zhang, Dai GC, Lu PP, Li YJ, Cao MM, Liu XY, Sheng RW, Shi L, Zhang C, Cui WG, Rui YF 2026 · Journal of advanced research | in-vitro | supports | low | QUERCETIN ALONE: in vitro, quercetin treatment of senescent human tendon stem/progenitor cells (TSPCs) significantly reduced SASP factor secretion and enhanced tenogenic differentiation via inhibited AKT phosphorylation (AKT/NF-kB/NLRP3 axi |
| Olson C et al 2026 · bioRxiv | animal | mixed | moderate | Preprint directly re-testing a prior claim that D+Q is senolytic in a focal cortical dysplasia mouse model: using longitudinal two-photon imaging + EEG at matched dose/timing, found only a modest reduction in ONE senescence marker (senomorp |
| Khan T, McFall DJ, Hussain AI, Frayser LA, Casilli TP, Steck MC, Sanchez-Brualla I, Kuehn NM, Cho M, Barnes JA, Harris BT, Vicini S, Forcelli PA 2026 · Annals of neurology | animal | mixed | moderate | Mixed genetic + D+Q COMBINATION approach: in a mouse pilocarpine temporal-lobe-epilepsy model, senolytic treatment (pooling a genetic senolysis model and pharmacological dasatinib+quercetin) produced a 50% reduction in senescent cells, resc |
| Koloko Ngassie ML, Drake LY, Zhu Y, Ortiz Y, Pfeffer-Kleemann DA, Thompson MA, Hamrick SK, Pabelick CM, Prakash YS 2026 · Aging cell | in-vitro | mixed | moderate | In human fetal airway smooth muscle cells under moderate hyperoxia (50% O2), D+Q [250nM+375nM] decreased beta-galactosidase activity, p21 and PAI-1 expression AND caused cell death (true senolysis), distinct from fucoidan (senomorphic, bloc |
| Lv J, Fan Q, Zhe J, Jiang S, Zhang Z, Wang H, Qin J, Cheng J, Wang L, Bao W 2026 · Science China. Life sciences | animal | mixed | low | In ovarian-cancer mouse models, the senolytic cocktail dasatinib+quercetin (and, separately, the NF-kB inhibitor resveratrol) alleviated cancer-induced adipose-derived stem cell senescence/adipose ageing, improved glucose tolerance/insulin |
| Keeble AR, Owen AM, Gonzalez-Velez S, Thomas NT, Brightwell CR, Balawender PJ, O'Daniel MG, Weiss HC, Noehren H, Thompson H, Zuluaga-Osorio KS, Bates ZT, Gottlieb L, Long DE, Harrison DA, Kern PA, Conley CE, Samaan MA, Duncan ST, Stone AV, Johnson DL, Wen Y, Noehren B, Dungan CM, Fry CS 2026 · Function (Oxford, England) | animal | mixed | moderate | D+Q cleared senescent macrophages (SPiDER-SA-beta-gal, single-cell resolution) and reduced muscle atrophy/cartilage degradation after ACL transection in mice, with greater clearance in muscle than cartilage; human ACL-injury/PTOA patients s |
| Hense JD, Isola JVV, Garcia DN, Zanini BM, Prosczek JB, Osório CAP, de Brito C, Mondal SA, Rice HC, Vaucher RA, Brieño-Enriquez MA, Mason JB, Masternak MM, Stout MB, Schneider A 2026 · Biology of reproduction | animal | mixed | low | D+Q in female mice with diet-induced MASLD attenuated ovarian senescence/inflammation/fibrosis and improved pregnancy rates, but had only limited effect on liver senescence/inflammation genes and liver mass despite MASLD being a liver-drive |
| Tong X et al 2026 · preprint | animal | mixed | low | D+Q COMBINATION: in a cadmium-induced osteocyte-senescence model, eliminating senescent cells with dasatinib plus quercetin 'markedly reduced osteocyte senescence' and improved bone integrity, with added benefit from co-treatment with melat |
| Karadagatla S, Padhy HP, Sharma A 2026 · Tissue & cell | in-vitro | mixed | low | In H2O2 (100uM)-induced senescent BEAS-2B lung epithelial cells, quercetin combined with ARTEMISININ (not dasatinib, not quercetin alone) reduced SA-beta-gal+ cells and the Atm/p53/p16/p21/Bcl-2 axis while suppressing SASP. Effect cannot be |
| Bian X, Snow ZK, Zinn CJ, Bratulin AL, Elhusseiny KM, Tchkonia T, Kirkland JL, Zhu Y, Khosla S, Kim SR, Lerman LO, Hickson LJ 2026 · EBioMedicine | animal | mixed | moderate | MAYO CLINIC / Kirkland-Tchkonia group study: D+Q (5+50 mg/kg, 5-day gavage) reduced kidney injury, fibrosis, p16Ink4a senescence and macrophage/senescence-associated inflammation in streptozotocin-diabetic mice and increased alpha-Klotho/Si |
| Yang B, Yang K, Xi R, Li S, Chen J, Wu Y 2025 · Redox biology | animal | mixed | low | D+Q COMBINATION: 4-month long-term dasatinib+quercetin treatment in a dry-AMD mouse model (Abca4-/-Rdh8-/-) 'effectively repressed cellular senescence,' lysosomal alkalinization, lipofuscin accumulation and oxidative stress in the RPE, alon |
| Sun SJ, Zhang Z, Zhang GY, Wu JJ, Zhang YX, Wu WB, Zhang Y, Yin H, Zhang JB, Cao Q, Wu JW, Shen FM, Zhou J, Li DJ, Wang P 2025 · Nature communications | animal | mixed | low | D+Q COMBINATION: in a GSDME-reintroduction mouse model of abdominal aortic aneurysm, the induced vascular senescence and AAA phenotype was 'abolished by senolytic therapy with dasatinib plus quercetin.' Combination dosing means the effect c |
| Heinrichs DP, Needy T, Maldonado V, Comer KD, Zotti M, Berryhill S, Cabrera AR, Jensen H, Murach KA, Barnes CL, Samsonraj RM 2026 · Biochimie | animal | mixed | low | Dasatinib+quercetin applied to senescent human mesenchymal stem cells produced inconsistent osteogenic/adipogenic differentiation and gene/protein expression results in vitro, increased extracellular-vesicle secretion, and showed unquantifi |
| Gonzales MM, Garbarino VR, Kautz TF, Palavicini JP, Lopez-Cruzan M, Dehkordi SK, Mathews JJ, Zare H, Xu P, Zhang B, Franklin C, Habes M, Craft S, Petersen RC, Tchkonia T, Kirkland JL, Salardini A, Seshadri S, Musi N, Orr ME 2023 · Nature medicine | observational | mixed | low | D+Q COMBINATION: open-label phase 1 trial in 5 early-stage AD patients (mean age 76+-5, 12 weeks) found only non-significant 'trending decreases' in senescence-related cytokines/chemokines in CSF, while IL-6 and GFAP significantly increased |
| Zhang M, Yang M, Sun Z, Qiu Z, Yang Z, Zhang Z, Li Y, Wang X, Huang X, Liu Q, Hou J, Yu B 2026 · Biochimica et biophysica acta. Molecular basis of disease | animal | mixed | low | In a study primarily about exercise/SIRT1 protecting against atherosclerosis via adipose-tissue aging, senolytic treatment (dasatinib+quercetin) was used as a pharmacological comparator and 'also attenuated eWAT aging and AS progression' - |
| Naito Y, Mizushima K, Inoue R, Takagi T 2026 · Nutrients | animal | supports | low | QUERCETIN ALONE (no dasatinib): a bioavailability-enhanced formulation (EubioQuercetin, EQN) reduced a composite external aging score in aged mice (median 4.5 vs 8, p<0.01) more than conventional quercetin (CQN, moderate reduction), and dow |
| Fujiwara M, Shinji S, Shichi Y, Nonaka K, Hasegawa Y, Takahashi K, Rokutan H, Arai T, Ishiwata T 2025 · BMC cancer | in-vitro | supports | low | QUERCETIN ALONE (tested separately from dasatinib, not combined): in FGFR4-inhibitor(BLU554)-induced senescent pancreatic ductal adenocarcinoma cell lines (PK-1, T3M-4), quercetin significantly reduced cell viability by ATP assay, indicatin |
| Gao F et al 2026 · bioRxiv | animal | mixed | moderate | Preprint: single-cell/spatial profiling of human valve/aortic specimens plus murine models identified senescent fibroblasts driving ECM-dominant cardiovascular disease; senolytic treatment (dasatinib+quercetin OR fisetin) restored ECM archi |
| Liu J, Ren X, Wang H, Yang D, Yan Y, Xu Y 2026 · Frontiers in pharmacology | animal | mixed | low | D+Q COMBINATION: in a rat model of radiation-induced lung injury (single 30Gy dose), DQ treatment decreased senescence markers p53, p21, and p16 and suppressed multiple SASP factors versus irradiation alone, alongside reduced fibrosis/colla |
| Calls-Cobos A, Beà Tàrrega A, Cisneros A, Rommelfanger M, Campanario S, Grima-Terrén M, Ramírez-Pardo I, Moiseeva V, Lukesova V, Andrés E, Chou G, Zheng Y, Hah N, Blasco-Roset A, Planavila A, Soler-Botija C, Bayés-Genís A, Perdiguero E, Serrano AL, Muñoz-Cánoves P 2026 · Skeletal muscle | animal | mixed | moderate | D+Q in DBA/2-mdx (Duchenne) mice: EARLY treatment (3-5mo) reduced senescent cell burden and fibrosis and improved fiber size/contractile force in skeletal muscle; LATE treatment reduced cardiac senescence/fibrosis but did not help skeletal |
| Qiao Y, Cheng X, Luo Z, Huang W, Zhang Z, Ren K, Xu X, He H, He M, Yin L 2026 · Redox report : communications in free radical research | animal | supports | moderate | QUERCETIN ALONE (no dasatinib), given either prophylactically (pre-bleomycin) or therapeutically (post-bleomycin) to mice, produced comparable fibrosis reduction, with the preventive regimen better limiting peaks of epithelial damage, ferro |
| Witkowski W et al 2026 · Apoptosis : an international journal on programmed cell death | in-vitro | mixed | low | A synthetic thioquercetin DERIVATIVE, thioQ(OAc)4 (modified quercetin, not natural quercetin, not combined with dasatinib), showed senolytic activity against cisplatin-induced senescent melanoma cells 'in selected experimental settings' - |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.